Global First Approval For Daiichi’s EZH1/2 Inhibitor Valemetostat In Japan
Ozoralizumab Also Gets First Nod
Executive Summary
Japan has granted to the first approval worldwide to Daiichi Sankyo’s dual EZH1/2 inhibitor valemetostat, for the treatment of adult T-cell leukemia/lymphoma. Taisho’s trivalent anti-TNFα nanobody ozoralizumab also received its global first approval, as part a large new batch of regulatory nods in the country.